Please login to the form below

lenalidomide

This page shows the latest lenalidomide news and features for those working in and with pharma, biotech and healthcare.

lenalidomide) and in ASCT-eligible patients could further expand the opportunity in previously-untreated patients.

Celgene’s Revlimid gets a win in late-stage lymphoma

The AUGMENT trial paired Revlimid (lenalidomide) with Roche’s established lymphoma therapy Rituxan (rituximab) in patient with two types of NHL – follicular lymphoma (FL) and marginal zone lymphoma (MZL) – and showed
Drugs for rare diseases will help propel pharma sales to $1.2trn by 2024; report

behind Celgene’s cancer immunomodulator Revlimid (lenalidomide).
Safety scuppers combo trials with J&J/Genmab’s Darzalex

Additional studies of Darzalex as an add-on to regimens based on Celgene’s Revlimid (lenalidomide) and in ASCT-eligible patients could further expand the opportunity in previously-untreated patients, says
FDA clears first-line use for J&J

Later on, additional studies of Darzalex as an add-on to regimens based on Celgene’s Revlimid (lenalidomide) and in ASCT-eligible patients could further expand the opportunity in previously-untreated
FDA clears first-line use for J&J’s myeloma drug Darzalex

Later on, additional studies of Darzalex as an add-on to regimens based on Celgene’s Revlimid (lenalidomide) and in ASCT-eligible patients could further expand the opportunity in previously-untreated

More from news
Approximately 14 fully matching, plus 79 partially matching documents found.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Add my company

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

The gene therapy revolution: Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...